A 510(k) is a premarket notification that asks the FDA to clear a device for the US market by proving it is substantially equivalent to an already-legally-marketed predicate device. Most Class II devices need one, and getting it right starts with a pre-submission meeting, not a finished dossier.
Manufacturers entering the US market for the first time often approach US FDA consulting specialists with a simple request: write us a 510(k). The reality is different. Classification, predicate selection and the shape of your evidence package get decided before a single form is filled in, and each of those decisions carries a real cost if it's wrong.
What is a 510(k) premarket notification?
A 510(k) premarket notification is the submission FDA reviews before most Class II devices, and some Class I devices, can enter the US market. It works by comparison rather than proof from scratch: you show FDA that your device is substantially equivalent to a predicate device already cleared or legally marketed in the US.
Some low-risk devices are exempt and can be listed with FDA without a review submission. Most devices above that threshold cannot go to market without a 510(k) clearance letter in hand. The FDA's own 510(k) premarket notification overview describes the pathway in full.
How does 510(k) clearance differ from a CE mark?
A CE mark and a 510(k) clearance test different things. CE marking under EU MDR verifies conformity against harmonised requirements through a notified body's assessment. A 510(k) verifies substantial equivalence to a US predicate device. Neither certification carries weight with the other regulator, so a CE-marked device still needs its own predicate search and its own FDA submission.
This catches out manufacturers who assume a strong EU regulatory position shortens the pathway to entering the US market. It doesn't. Predicate selection, technological comparison and FDA's own review clock all run independently of your CE history.
What is a predicate device, and how do you identify one?
A predicate device is a legally marketed US device with the same intended use as the device under review, evaluated against it for technological characteristics. Recently cleared devices with no unresolved safety issues or recalls make the safest predicate choice. A weak predicate is one of the most common reasons FDA sends an Additional Information request.
- Same intended use and indications for use as your device
- Similar technological characteristics: design, materials, energy source, performance
- Cleared via well-established methods, without an associated safety signal or recall
- A single predicate is preferred; FDA's guidance on preparing a traditional 510(k) treats “split predicates”, combining features from multiple devices, as inconsistent with the 510(k) standard
Predicate selection isn't a formality. It sets the boundaries of every comparison that follows, and a predicate chosen for convenience rather than fit tends to surface as an FDA question three months into review rather than a problem caught before submission.
How do you demonstrate substantial equivalence?
Substantial equivalence means your device shares the predicate's intended use, and either shares its technological characteristics or differs in ways that don't raise new questions of safety or effectiveness, supported by data. Equivalence isn't sameness. It's a defensible comparison, and the comparison itself is what FDA reviewers scrutinise most closely.
Demonstrating equivalence well enough to avoid a full clinical investigation is usually the single biggest cost saving available in a US market entry strategy. Getting the comparison wrong is also the single biggest source of delay.
When is a 510(k) required, and when do you need a different pathway?
Whether you need a 510(k) depends on risk. Devices comparable to EU Class I are often 510(k) exempt. Medium-risk devices typically need a standard 510(k). Higher-risk devices, or devices with no suitable predicate, may need De Novo classification or full Premarket Approval instead.
- Lower-risk devices: often 510(k) exempt, listed with FDA without a review submission
- Medium-risk devices: the standard 510(k) pathway, built on predicate comparison
- Novel devices with no suitable predicate: De Novo classification, a risk-based route into Class I or II
- Higher-risk devices: Premarket Approval (PMA), the most evidence-intensive route
What are the three types of 510(k) submissions?
FDA recognises three 510(k) types: Traditional, Special and Abbreviated. A Special 510(k) relies on your own design controls to support equivalence for a modified version of your own already-cleared device. An Abbreviated 510(k) leans on FDA-recognised standards or guidance instead of a side-by-side predicate comparison. Traditional is the default when neither applies.
Choosing the wrong type doesn't just cost time. It can trigger a Refuse to Accept decision before FDA even begins substantive review.
Why does a pre-submission (Q-Sub) meeting matter?
A pre-submission meeting, or Q-Sub, lets you ask FDA specific questions about your strategy before you commit resources to it. It's not a formality: FDA's written or verbal feedback on your classification, predicate choice or test protocol becomes your working guidance for the submission that follows, and skipping it is one of the most common ways manufacturers waste testing budget.
- Feedback on your proposed classification and predicate device
- Biocompatibility or performance testing strategy, before you run the tests
- Any other regulatory concern specific to your device or indication
How does the pre-submission process work?
The Q-Sub process follows a fixed structure. Questions go to FDA in a defined format under the Q-Submission Program guidance, you choose a written response or a meeting, and FDA's answer becomes the basis for both your product development plan and your eventual 510(k).
- Submit your questions to FDA in the structured format the Q-Submission Program requires
- Request either a written response or, more commonly, a meeting with FDA reviewers
- Use FDA's feedback to finalise your test plan and submission strategy before you invest in testing
How long does FDA review take, and what does it cost?
FDA's MDUFA V goal is a decision on 95% of 510(k)s within 90 FDA review days, though time spent on an Additional Information hold doesn't count against that clock, so calendar time typically runs longer. The FY2026 510(k) user fee is $26,067 standard, or $6,517 for a qualifying small business.
Budget for the fee, the testing behind your comparison, and the internal time a well-run pre-submission and interactive review demand. The fee is usually the smallest line item in the submission.
What are the most common 510(k) submission pitfalls?
The most frequent 510(k) problem isn't the paperwork. It's technical documentation that doesn't yet meet FDA's expectations: gaps in the predicate comparison, testing that doesn't match the device's actual indications, or a submission assembled before the underlying data was ready.
A Class II diagnostic device with a technically sound predicate can still draw an Additional Information request if the comparison table omits a performance metric the predicate's own FDA summary reported. Reviewers compare line by line, not impression by impression.
- Identifying documentation gaps against FDA's actual expectations, not assumptions carried over from CE technical files
- Bringing documentation into line with current FDA guidance
- Assembling a submission package that addresses every requirement the device's classification triggers
Getting your 510(k) strategy right
The FDA 510(k) process rewards strategy over speed. A pre-submission meeting, a well-chosen predicate and a defensible equivalence argument save far more time than they cost, and each is decided long before a submission is drafted.
Qserve's US FDA consulting team runs predicate searches, prepares Q-Sub meetings and compiles submission dossiers for manufacturers moving from CE marking to US clearance, or bringing a first device to market in either region. Talk to the team to scope your submission strategy.